ECHO PHARMACEUTICALS ANNOUNCES SUCCESSFUL PHASE 2 RESULTS FOR NAMISOL®

Amsterdam, Netherlands, Cambridge UK, and Clinton NJ – July 2013 – Echo Pharmaceuticals (“Echo”) announces that Namisol® has completed successfully a Phase II trial with 24 patients suffering from spasticity and pain due to multiple sclerosis.

The clinical trial has been conducted by the Centre for Human Drug Research in the VU University Medical Center Amsterdam and was a double blind, placebo-controlled study to determine safety, tolerability and efficacy for MS patients. The outcome of this trial showed efficacy and consistent results on both spasticity and pain. The Sage Group has been appointed by Echo Pharmaceuticals to assist in the search for a strategic partner for commercialization of its lead Namisol® program.
Dr. Vanesa Fernandez, CEO of Echo Pharmaceuticals: “We are very pleased that The Sage Group has accepted to assist in the commercialization phase of Namisol®. The successful Phase 2 trial in MS patients is a major milestone for Echo and we believe there will be strong global interest in working with us to take the product to market. The Sage Group are very experienced in developing such partnerships and will add a valuable business development activity to our drug development capability”.

For more information visit: www.echo-pharma.com

		stdClass Object
(
    [vid] => 21
    [uid] => 1
    [title] => 12 jul 2013
    [log] => 
    [status] => 1
    [comment] => 1
    [promote] => 1
    [sticky] => 1
    [nid] => 21
    [type] => nieuws
    [language] => nl
    [created] => 1376052130
    [changed] => 1378285747
    [tnid] => 0
    [translate] => 0
    [revision_timestamp] => 1378285747
    [revision_uid] => 1
    [body] => Array
        (
            [nl] => Array
                (
                    [0] => Array
                        (
                            [value] => 

ECHO PHARMACEUTICALS ANNOUNCES SUCCESSFUL PHASE 2 RESULTS FOR NAMISOL®

Amsterdam, Netherlands, Cambridge UK, and Clinton NJ – July 2013 – Echo Pharmaceuticals (“Echo”) announces that Namisol® has completed successfully a Phase II trial with 24 patients suffering from spasticity and pain due to multiple sclerosis.

The clinical trial has been conducted by the Centre for Human Drug Research in the VU University Medical Center Amsterdam and was a double blind, placebo-controlled study to determine safety, tolerability and efficacy for MS patients. The outcome of this trial showed efficacy and consistent results on both spasticity and pain. The Sage Group has been appointed by Echo Pharmaceuticals to assist in the search for a strategic partner for commercialization of its lead Namisol® program.
Dr. Vanesa Fernandez, CEO of Echo Pharmaceuticals: “We are very pleased that The Sage Group has accepted to assist in the commercialization phase of Namisol®. The successful Phase 2 trial in MS patients is a major milestone for Echo and we believe there will be strong global interest in working with us to take the product to market. The Sage Group are very experienced in developing such partnerships and will add a valuable business development activity to our drug development capability”.

For more information visit: www.echo-pharma.com

[summary] => [format] => full_html [safe_value] =>

ECHO PHARMACEUTICALS ANNOUNCES SUCCESSFUL PHASE 2 RESULTS FOR NAMISOL®

Amsterdam, Netherlands, Cambridge UK, and Clinton NJ – July 2013 – Echo Pharmaceuticals (“Echo”) announces that Namisol® has completed successfully a Phase II trial with 24 patients suffering from spasticity and pain due to multiple sclerosis.

The clinical trial has been conducted by the Centre for Human Drug Research in the VU University Medical Center Amsterdam and was a double blind, placebo-controlled study to determine safety, tolerability and efficacy for MS patients. The outcome of this trial showed efficacy and consistent results on both spasticity and pain. The Sage Group has been appointed by Echo Pharmaceuticals to assist in the search for a strategic partner for commercialization of its lead Namisol® program.
Dr. Vanesa Fernandez, CEO of Echo Pharmaceuticals: “We are very pleased that The Sage Group has accepted to assist in the commercialization phase of Namisol®. The successful Phase 2 trial in MS patients is a major milestone for Echo and we believe there will be strong global interest in working with us to take the product to market. The Sage Group are very experienced in developing such partnerships and will add a valuable business development activity to our drug development capability”.

For more information visit: www.echo-pharma.com

[safe_summary] => ) ) ) [field_banner] => Array ( [und] => Array ( [0] => Array ( [fid] => 11 [uid] => 1 [filename] => recycling_waste.jpg [uri] => public://default_images/recycling_waste.jpg [filemime] => image/jpeg [filesize] => 342626 [status] => 1 [timestamp] => 1375988880 [rdf_mapping] => Array ( ) [is_default] => 1 [alt] => [title] => ) ) ) [field_liggende_image] => Array ( ) [field_staande_image] => Array ( ) [field_datum] => Array ( [und] => Array ( [0] => Array ( [value] => 2013-07-12T00:00:00 [timezone] => Europe/Amsterdam [timezone_db] => Europe/Amsterdam [date_type] => date ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => small ) ) ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_black ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => white ) ) ) [field_video] => Array ( ) [field_subtitel] => Array ( [und] => Array ( [0] => Array ( [value] => Echo Pharmaceuticals announces successful [format] => [safe_value] => Echo Pharmaceuticals announces successful ) [1] => Array ( [value] => phase 2 results for Namisol® [format] => [safe_value] => phase 2 results for Namisol® ) ) ) [field_gerelateerde_industrie_n] => Array ( [und] => Array ( [0] => Array ( [target_id] => 20 [entity] => stdClass Object ( [vid] => 20 [uid] => 1 [title] => Pharmaceutical and Biomedical [log] => [status] => 1 [comment] => 1 [promote] => 1 [sticky] => 0 [nid] => 20 [type] => industries [language] => nl [created] => 1376039461 [changed] => 1492505610 [tnid] => 0 [translate] => 0 [revision_timestamp] => 1492505610 [revision_uid] => 1 [body] => Array ( [nl] => Array ( [0] => Array ( [value] =>

Healthy people and a Healthy planet

That is what FeyeCon aims for. Using CO₂ based processes for drug isolation, purification and formulation we create completely new and improved pharmaceutical and biomedical products. Our CO₂ technology is mild and leaves no residual solvents. It offers a very versatile and tunable process.  

Our mild and versatile CO₂ technology achieves:

  • High drug bioavailability
  • Increased product shelf-life
  • Improved patient wellbeing
  • Straightforward GMP upscaling

Our particles are characterized by:

  • High bioavailability
  • Tunable particle properties: size, morphology, density, crystal structures, polymorphisms
  • Tunable drug release properties
  • Full structural preservation of sensitive drugs
  • Different routes of administration

GMP Clean Room Facility 

At our laboratory in Weesp, The Netherlands, we have cGMP facilities that operate supercritical CO₂ equipment available to external parties. Our facilities - including a certified class D cleanroom - allow for the cGMP production of clinical batches and contract manufacturing.

Read more about our Pharmaceutical and Biomedical Technology

[summary] => [format] => full_html [safe_value] =>

Healthy people and a Healthy planet

That is what FeyeCon aims for. Using CO₂ based processes for drug isolation, purification and formulation we create completely new and improved pharmaceutical and biomedical products. Our CO₂ technology is mild and leaves no residual solvents. It offers a very versatile and tunable process.  

Our mild and versatile CO₂ technology achieves:

  • High drug bioavailability
  • Increased product shelf-life
  • Improved patient wellbeing
  • Straightforward GMP upscaling

Our particles are characterized by:

  • High bioavailability
  • Tunable particle properties: size, morphology, density, crystal structures, polymorphisms
  • Tunable drug release properties
  • Full structural preservation of sensitive drugs
  • Different routes of administration

GMP Clean Room Facility 

At our laboratory in Weesp, The Netherlands, we have cGMP facilities that operate supercritical CO₂ equipment available to external parties. Our facilities - including a certified class D cleanroom - allow for the cGMP production of clinical batches and contract manufacturing.

Read more about our Pharmaceutical and Biomedical Technology

[safe_summary] => ) ) ) [field_banner] => Array ( [und] => Array ( [0] => Array ( [fid] => 369 [uid] => 1 [filename] => shutterstock_105030071.jpg [uri] => public://banner/shutterstock_105030071.jpg [filemime] => image/jpeg [filesize] => 6251924 [status] => 1 [timestamp] => 1489152377 [rdf_mapping] => Array ( ) [alt] => [title] => [width] => 4928 [height] => 3264 ) ) ) [field_blok_achtergrond] => Array ( [und] => Array ( [0] => Array ( [value] => bg_image ) ) ) [field_blok_grootte] => Array ( [und] => Array ( [0] => Array ( [value] => big ) ) ) [field_blok_tekstkleur] => Array ( [und] => Array ( [0] => Array ( [value] => black ) ) ) [field_liggende_image] => Array ( ) [field_staande_image] => Array ( [und] => Array ( [0] => Array ( [fid] => 370 [uid] => 1 [filename] => shutterstock_105030071.jpg [uri] => public://content_staand/shutterstock_105030071.jpg [filemime] => image/jpeg [filesize] => 6251924 [status] => 1 [timestamp] => 1489152377 [rdf_mapping] => Array ( ) [alt] => [title] => [width] => 4928 [height] => 3264 ) ) ) [field_subtitel] => Array ( ) [field_video] => Array ( ) [field_icoon] => Array ( [und] => Array ( [0] => Array ( [fid] => 21 [uid] => 1 [filename] => icon_lifescience.png [uri] => public://industrieen/icon_lifescience.png [filemime] => image/png [filesize] => 313 [status] => 1 [timestamp] => 1376039461 [rdf_mapping] => Array ( ) [alt] => Life Science & Health care [title] => Life Science & Health care [width] => 31 [height] => 31 ) ) ) [field_gerelateerde_producten] => Array ( [und] => Array ( [0] => Array ( [target_id] => 32 ) [1] => Array ( [target_id] => 30 ) [2] => Array ( [target_id] => 28 ) [3] => Array ( [target_id] => 31 ) ) ) [field_gerelateerde_business_vent] => Array ( [und] => Array ( [0] => Array ( [target_id] => 41 ) [1] => Array ( [target_id] => 37 ) [2] => Array ( [target_id] => 52 ) [3] => Array ( [target_id] => 54 ) [4] => Array ( [target_id] => 39 ) [5] => Array ( [target_id] => 36 ) ) ) [field_sortering] => Array ( [und] => Array ( [0] => Array ( [value] => 4 ) ) ) [field_pagina_images] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1376039461 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} ) [access] => 1 ) ) ) [field_pagina_images] => Array ( ) [field_attachment] => Array ( ) [rdf_mapping] => Array ( [rdftype] => Array ( [0] => sioc:Item [1] => foaf:Document ) [title] => Array ( [predicates] => Array ( [0] => dc:title ) ) [created] => Array ( [predicates] => Array ( [0] => dc:date [1] => dc:created ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [changed] => Array ( [predicates] => Array ( [0] => dc:modified ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) [body] => Array ( [predicates] => Array ( [0] => content:encoded ) ) [uid] => Array ( [predicates] => Array ( [0] => sioc:has_creator ) [type] => rel ) [name] => Array ( [predicates] => Array ( [0] => foaf:name ) ) [comment_count] => Array ( [predicates] => Array ( [0] => sioc:num_replies ) [datatype] => xsd:integer ) [last_activity] => Array ( [predicates] => Array ( [0] => sioc:last_activity_date ) [datatype] => xsd:dateTime [callback] => date_iso8601 ) ) [cid] => 0 [last_comment_timestamp] => 1376052130 [last_comment_name] => [last_comment_uid] => 1 [comment_count] => 0 [name] => feyecon-admin [picture] => 0 [data] => a:3:{s:7:"overlay";i:1;s:18:"htmlmail_plaintext";i:0;s:7:"contact";i:0;} [entity_view_prepared] => 1 )